acetaminophenacetaminophen will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Feature	Flibanserin	Bremelanotide	Vyleesi
Approved for HSDD	Yes	No	Yes
Administration Route	Oral	Injectable	Injectable
Usage Frequency	Daily	As needed	As needed
Main Side Effects	Dizziness, nausea	Nausea, flushing	Nausea, reactions at injection site

Increased flibanserin adverse effects may occur if coadministered with multiple weak CYP3A4 inhibitors. acetaminophen will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. acetaminophen IVacetaminophen IV will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. acetaminophen IV will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. acetaminophen rectal will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Availability and cost

flibanserin will increase the level or effect of rimegepant by P-glycoprotein (MDR1) efflux transporter. ropeginterferon alfa 2bropeginterferon alfa 2b and flibanserin both increase Other (see comment). Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity. ropeginterferon alfa 2b and flibanserin both increase Other (see comment).

Does Addyi interact with foods or drinks?

tucatinibtucatinib will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid concomitant use of tucatinib with CYP3A substrates, where minimal concentration changes may lead to serious or life-threatening toxicities. If unavoidable, reduce CYP3A substrate dose according to product labeling. tucatinib will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. venetoclaxflibanserin will increase the level or effect of venetoclax by P-glycoprotein (MDR1) efflux transporter. acetaminophen/phenyltoloxamine and flibanserin both increase sedation. Risk for sedation increased if flibanserin is coadministration with other CNS depressants. amlodipineamlodipine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. amlodipine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Product	Dosage	Quantity + Bonus	Price
Levitra Soft Tabs	20mg	360 + 20 Pills	682.21€ 649.72€
Cialis Generic	40mg	360 + 10 Pills	477.87€ 455.11€
Cialis Original	20mg	14 + 2 Pills	95.75€ 91.19€
Levitra Generic	40mg	30 + 2 Pills	93.58€ 89.12€
Kamagra Soft Tabs	100mg	180 + 8 Pills	425.45€ 405.19€
Viagra Generic	200mg	180 + 10 Pills	277.56€ 264.34€
Cialis Professional	40mg	270 + 6 Pills	898.37€ 855.59€
Kamagra Soft Tabs	100 mg	84 + 4 Pills	233.05€ 221.95€
Viagra Professional	100mg	10 Pills	44.09€ 41.99€
Viagra Generic	50mg	270 + 8 Pills	198.48€ 189.03€
Cialis Generic	60mg	10 Pills	41.22€ 39.26€
Cialis Generic	40mg	90 + 6 Pills	171.35€ 163.19€
Kamagra Soft Tabs	100 mg	12 Pills	57.55€ 54.81€
Cialis Black	80mg	360 + 20 Pills	639.78€ 609.31€
Viagra Soft Tabs	100mg	120 + 8 Pills	232.21€ 221.15€
Viagra Professional	100mg	20 Pills	71.14€ 67.75€

Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. armodafinilarmodafinil will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. armodafinil will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Information & Authors

ivosidenib will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. lonafarniblonafarnib will increase the level or effect of flibanserin by affecting hepatic enzyme CYP2C19 metabolism. Lonafarnib may increase the AUC and peak concentration of CYP2C19 substrates. If coadministration unavoidable, monitor for adverse reactions and reduce the CYP2C19 substrate dose in accordance with its approved product labeling. lonafarnib will increase the level or effect of flibanserin by affecting hepatic enzyme CYP2C19 metabolism.

How do I store and/or throw out this drug?

lorlatiniblorlatinib will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. lorlatinib will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Either increases effects of the other by Other (see comment). Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. asenapine transdermalasenapine transdermal and flibanserin both increase sedation.

Flibanserin's journey from failed antidepressant to HSDD treatment is unique.
Its development cost hundreds of millions of dollars over two decades.
The FDA initially rejected it in 2010 and 2013 due to safety/efficacy concerns.
Final 2015 approval came with the stringent REMS and boxed warning.
The approval process involved patient testimony and advocacy efforts.
It is classified as a multifunctional serotonin agonist and antagonist (MSAA).
Does not bind significantly to dopamine, norepinephrine, or histamine receptors.
Binding affinity is highest for serotonin 5-HT1A and 5-HT2A receptors.
Its metabolite, 6-hydroxy-flibanserin, is inactive.

asenapine transdermal and flibanserin both increase sedation. atorvastatinatorvastatin will increase the level or effect of cenforce 100 uk flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. atorvastatin will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Global availability varies; approved in the US, Canada, and some other countries.
Not approved in the European Union by the EMA as of current knowledge.
Different brand names may be used in countries where it is marketed.
Importing for personal use from other countries carries risks and is often illegal.
Counterfeit versions of the medication are a potential danger.
Patients should only obtain it from a certified, licensed pharmacy.
Telemedicine may be used for consultations but REMS requirements still apply.
The future of flibanserin may involve generic competition reducing cost.
Research into its potential effects on other conditions (e.g., depression) is limited.

azelastineazelastine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. azelastine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. belzutifanbelzutifan will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. If unable to avoid coadministration of belzutifan with sensitive CYP3A4 substrates, consider increasing the sensitive CYP3A4 substrate dose in accordance with its prescribing information. belzutifan will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Either increases effects of the other by serotonin levels. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment.benzhydrocodone/acetaminophen and flibanserin both increase sedation. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment. berotralstatflibanserin increases levels of berotralstat by P-glycoprotein (MDR1) efflux transporter.

dopamine, norepinephrine, and serotonin3

Use of any colchicine product in conjunction with P-gp inhibitors is contraindicated in patients with renal or hepatic impairment. flibanserin increases levels of colchicine by P-glycoprotein (MDR1) efflux transporter. Strong CYP3A4 inducers substantially decrease flibanserin systemic exposure. eslicarbazepine acetate will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. fexinidazolefexinidazole will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Pediatric Precautions

Coadministration may increase risk for adverse effects of CYP3A4 substrates. fexinidazole will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. ivosidenibivosidenib will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid coadministration of sensitive CYP3A4 substrates with ivosidenib or replace with alternate therapies. If coadministration is unavoidable, monitor patients for loss of therapeutic effect of these drugs. flibanserin increases levels of berotralstat by P-glycoprotein (MDR1) efflux transporter. betamethasonebetamethasone will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. betamethasone will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. bortezomibbortezomib will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. bortezomib will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. bosentanbosentan will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

IMPORTANT WARNING:

ozanimodozanimod increases toxicity of flibanserin by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Because the active metabolite of ozanimod inhibits MAO-B in vitro, there is a potential for serious adverse reactions, including hypertensive crisis. Therefore, coadministration of ozanimod with drugs that can increase norepinephrine or serotonin is not recommended. ozanimod increases toxicity of flibanserin by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. flibanserin will increase the level or effect of repotrectinib by P-glycoprotein (MDR1) efflux transporter.

Last Reviewed Date

ribociclibribociclib will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. ribociclib will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. rilzabrutinibrilzabrutinib will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Follow substrate recommendations for use with moderate CYP3A inhibitors rilzabrutinib will increase the level or effect of flibanserin by fildena 200 mg affecting hepatic/intestinal enzyme CYP3A4 metabolism. Follow substrate recommendations for use with moderate CYP3A inhibitors rimegepantflibanserin will increase the level or effect of rimegepant by P-glycoprotein (MDR1) efflux transporter. bosentan will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Side effects

If a P-gp inhibitor must be used, reduce the venetoclax dose by at least 50%. Monitor more closely for signs of venetoclax toxicities. flibanserin will increase the level or effect of venetoclax by P-glycoprotein (MDR1) efflux transporter. Either increases effects of the other by pharmacodynamic synergism. Coadministration of zuranolone with other CNS depressants may increase impairment of psychomotor performance or CNS depressant effects. Either increases toxicity of the other by sedation. brimonidine topicalbrimonidine topical and flibanserin both increase sedation. brimonidine topical and flibanserin both increase sedation.

Potential for negative publicity and stigma surrounding a "pink Viagra."
Media coverage often oversimplifies its mechanism and expected results.
Patient education is crucial to set realistic expectations about benefits.
Support groups and online communities exist for women discussing HSDD treatment.
Ongoing research continues to explore other pharmacologic targets for HSDD.
Future developments may include new formulations or combination therapies.
The approval of flibanserin spurred increased investment in female sexual health.
It remains a subject of debate in medical ethics, women's health, and drug regulation.
Prescribers should stay updated on post-marketing safety communications.

bromocriptinebromocriptine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. bromocriptine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. buprenorphine buccalbuprenorphine buccal and flibanserin both increase sedation. buprenorphine buccal and flibanserin both increase sedation. buprenorphine subdermal implantbuprenorphine subdermal implant and flibanserin both increase sedation.

Aspect	Explanation
Serotonin Receptor Modulation	Acts as a 5-HT1A receptor agonist and 5-HT2A antagonist
Effect on Neurotransmitters	Balances serotonin, dopamine, and norepinephrine activity
Impact on Sexual Desire	Enhances desire by modulating serotonergic inhibition of dopamine pathways

buprenorphine subdermal implant and flibanserin both increase sedation.